Dr. Miele Cosmed Group S.A. (DMG.WA)

Dr. Miele Cosmed Group S.A. (DMG.WA) — VMCI valuation read

Dr. Miele Cosmed Group S.A. (DMG.WA) carries a VMCI composite of 61/100, 11 points above the Consumer Defensive sector median of 50. Among mid-cap names, that gap places DMG.WA in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The DMG.WA insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads DMG.WA trades at 20.0x earnings, 11% above the Consumer Defensive median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Consumer Defensive 12.0x. Quality: ROIC of 18.0% sits 8.0pp above the Consumer Defensive median (10.0%). Risk: net debt to EBITDA of -1.3x leaves covenant headroom, the line to track on Dr. Miele Cosmed Group S.A.'s next 10-Q.

DMG.WA fell 0.6% over the trailing 7 days, with a -5.8% read on a 30-day basis.